Description

Imaget 400 mg contains Imatinib, a first-generation tyrosine kinase inhibitor (TKI) widely used in the treatment of hematologic and certain solid tumors. It is administered orally and has transformed the management of CML and other targeted cancers.

🔬 Mechanism of Action

Imatinib selectively inhibits several tyrosine kinases, including:

• BCR-ABL (Philadelphia chromosome-positive leukemia)
• c-KIT
• PDGFR (Platelet-Derived Growth Factor Receptor)

By blocking these abnormal signaling pathways, Imaget 400 mg:

• Stops cancer cell proliferation
• Induces apoptosis (cell death)
• Helps control disease progression

💊 Indications of Imaget 400 mg

Imaget 400 mg is indicated for:

• Chronic Myeloid Leukemia (CML)
• Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)
• Gastrointestinal Stromal Tumors (GIST)
• Myelodysplastic/Myeloproliferative diseases (MDS/MPD)
• Hypereosinophilic syndrome (HES)
• Other KIT or PDGFR-positive malignancies

📌 Key Features of Imaget 400 mg

• Strength: 400 mg
• Dosage Form: Oral tablet
• Therapeutic Class: Tyrosine Kinase Inhibitor (TKI)
• Administration: Taken orally once daily with food and water
• Monitoring: Regular complete blood counts (CBC) and liver function tests required

⚕️ Benefits of Imatinib

• Targeted therapy for specific genetic mutations
• Improves long-term survival in CML
• Oral administration for patient convenience
• Effective in both hematologic and certain solid tumors

⚠️ Precautions

• May cause edema, nausea, muscle cramps, and fatigue
• Risk of liver toxicity
• Regular blood monitoring required
• Dose adjustments may be needed based on response and tolerance
• Use strictly under oncologist or hematologist supervision

Imaget 400 mg (Imatinib Tablets) is a cornerstone targeted therapy in modern oncology and hematology, providing effective long-term disease control in CML and other kinase-driven cancers when administered under specialized medical care.